Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 5;12:731609. doi: 10.3389/fphar.2021.731609

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Wang, Ma, Zhang, Li, Hong, Jiang, Duan and Liu.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Effects of GPR30 agonist G1 on the expression of p-ERK1/2, ERK1/2, and MMP-9 protein in DOX/Ang II-treated cardiomyocytes and on the expression of TGF-β1 in cardiac fibroblast. (A) Primary CFs express vimentin and are negative for troponin, which is consistent with the characteristics of primary cultured cardiac fibroblasts. (B) Representative images of Western blot. (C) p-ERK1/2 to ERK1/2. (D) MMP-9 expression. (E) The content of MMP-9 in the culture medium of cardiomyocytes. (F) Representative images of Western blot. (G) TGF-β1 expression. The results were expressed as mean ± S.E.M, n = 3. *p < 0.05 compared with the Dox group, #p < 0.05 compared with the Dox + Ang Ⅱ group.